Skip to main content

Table 2 Details and Outcomes of the patients treated with anti-TNF alpha antibodies

From: Infliximab therapy for Crohn’s-like disease in common variable immunodeficiency complicated by massive intestinal hemorrhage: a case report

Case# Anti-TNF alpha Duration of anti-TNF* alpha therapy Combined azathoprine Side effects Response to anti-TNF alpha therapy
1 Infliximab 1 year (discontinued) Yes No Remission
2 Adalibmab More than 1 year (discontinued) Yes No Partial response
3 Infliximab Several weeks (continued) Yes No Remission
4 Infliximab 4 weeks (discontinued) No No Remission
  1. *TNF: tumor nerosis factor.